8-K
filed May 13, 2026, 4:03 PM ET
ticker VRTX
CIK 0000875320
other material
confidence high
sentiment neutral
materiality 0.50
Vertex shareholders approve 2026 Stock Plan, all director nominees, and shareholder written consent proposal
VERTEX PHARMACEUTICALS INC / MA
- All 10 director nominees elected; CEO Reshma Kewalramani received ~221.9M votes.
- Shareholders ratified Ernst & Young as independent auditor for 2026 (223.5M for).
- Advisory say-on-pay passed with 207.9M votes for vs. 14.5M against.
- 2026 Stock and Option Plan approved (216.1M for, 6.5M against), replacing 2013 plan.
- Shareholder proposal for right to act by written consent passed (126.9M for vs. 95.8M against).
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA shareholders approved Advisory approval of 2025 named executive officer compensation program at the 2026-05-13 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-13
Exact text from the filing
Based upon the following votes, the shareholders approved, on an advisory basis, the 2025 compensation program for the Company's named executive officers:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA shareholders approved Election of 10 directors to serve until 2027 annual meeting at the 2026-05-13 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-13
Exact text from the filing
Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider and Nancy Thornberry to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2027
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for 2026 at the 2026-05-13 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-13
Exact text from the filing
Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA shareholders approved Approval of the Company's 2026 Stock and Option Plan at the 2026-05-13 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-13
Exact text from the filing
Based upon the following votes, the shareholders approved the Company's 2026 Stock and Option Plan.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
VERTEX PHARMACEUTICALS INC / MA shareholders approved Shareholder proposal regarding shareholder right to act by written consent at the 2026-05-13 meeting.
- Outcome
- passed
- Meeting
- 2026-05-13
Exact text from the filing
Based upon the following votes, the shareholders approved a shareholder proposal regarding shareholder right to act by written consent:
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.